Post-Conference Workshop Day

Explore the Agenda

Pre-Conference Day

Monday, 23rd February

Day One

Tuesday, 24th February

Day Two

Wednesday, 25th February

Post-Conference Day

Thursday, 26th February

8:00 am Check In, Morning Coffee & Light Refreshments

Workshop A Workshop B Workshop C Workshop D

Workshop A

Tailored to Discovery Content

9:00 am Examining The Need for Novel ADC Payload Mechanisms: What Progress Has Been Made & What is Yet to be Demonstrated?

Ines Matos

Principal Scientist, Roche

Thierry Guillaudeux

Executive Director & Head, R&D France, Eli Lilly & Co.

As the ADC landscape becomes busier and more crowded around validated Topo1 and MMAE payloads, the need for differentiated mechanisms is vital to ensure future conjugates can overcome anticipated resistance and deliver patient benefit

Join this workshop session to navigate the different avenues of novel payload development, assessing the emerging performance of cytotoxic, non-cytotoxic and dual payload approaches to discuss and debate the next payload wave to replace topoisomerase inhibitors

Workshop highlights include:

Discussing the crucial need for novel ADC payloads in the face of crowded clinical landscapes and future patient resistance mechanisms
Weighing up risk level against novelty of mechanism when approaching novel payload development: What linker payloads are showing the most promise so far?
Evaluating the opportunity for dual payload ADCs and combination therapies to combat patient resistance

Workshop B

Tailored for Preclinical & Translation Content

9:00 am Using Computational Approaches for Early-Stage Design & Late-Stage ADC Development

Greg Thurber

Professor, Chemical & Biomedical Engineering, University of Michigan

As the ADC community looks to broaden its scope beyond purely in vivo preclinical approaches, the use of AI, machine learning, and computational approaches provide a powerful opportunity to predict ADC properties and behaviour, especially against mismatched readouts between traditional preclinical studies and clinical trials

Don’t miss this workshop led by ADC KOL Greg Thurber to investigate the implementation, of in silico, models and simulators to predict how ADC design influences efficacy

Workshop highlights include:

Exploring the multiscale mechanisms of ADC distribution, from subcellular to cellular, tissue, organ, and systemic biodistribution
Discussing the (sometimes) counterintuitive results of ADC efficacy between animal models and the clinic
Reviewing the practical implementation of ADC simulations to predict how ADC design impacts efficacy

Workshop C

Tailored to Clinical Lessons Content

9:00 am Connecting ADC Design to Performance: How is Each Component Contributing to ADC Clinical Safety & Efficacy?

Jutta Deckert

Vice President, R&D, Iksuda Therapeutics

Bob Lutz

Chief Scientific Officer, Iksuda Therapeutics

As an increasingly diverse array of ADCs containing different payloads and linkers are developed to tackle different tumour targets, understanding how bioconjugate design contributes and accumulates to performance, especially in the clinic, is vital to set up your therapy for success

Take part in this workshop exploring case-study examples to contextualise and understand the performance of different ADC designs to understand what really makes a clinically effective ADC

Workshop highlights include:

Accurately correlating and characterising antibody, linker, payload, and overall conjugate contributions to ADC clinical performance
Delving into ADC clinical case studies to understand differentiated design impact on clinical safety and efficacy profiles
Finding the right match: optimising ADC design to optimise payload target pairing

Workshop D

Tailored to Process & Analytical Development Content

9:00 am Understanding Process Control & Scale-Up to Develop Robust Processes for Complex Conjugates Across Development Stages

Tim Mollner

Senior Expert, Novartis

Developing, optimising and maturing ADC process is the cornerstone to streamline ADC manufacturing and demonstrate confidence to regulatory bodies

Spanning process scale-up from preclinical phase up to GMP manufacturing, this workshop is your best opportunity to converse with ADC technical experts on all facets of process development including in-process impurity control and post-conjugation purification to guarantee your ADC product quality

Workshop highlights include:

Navigating ADC process scale up from early preclinical phase, through GLP toxicity, to GMP manufacturing
Understanding the use and applications of inprocess controls in ADC drug-linker synthesis and conjugation
Exploring process development and post conjugation purification for increasingly complex bioconjugates

12:00 pm Lunch & Networking

Workshop E Workshop F Workshop G Workshop H

Workshop E

Tailored to Discovery Content

1:00 pm Deep Diving into ADC Chemistry Conjugation to Understand the Fundamentals Behind Next-Generation ADC Properties & Design

Michael Seganish

Distinguished Scientist, Discovery Chemistry, MSD

Understanding the challenges and opportunities at the forefront of ADC conjugation is vital to optimise ADC design, DAR and therapeutic properties capabilities from the get-go

Join this workshop to secure your understanding of fundamental principles of ADC conjugation, assess the pros and cons of next-generation site-specific technologies and explore how best to approach conjugation design with clinical differentiation in mind

Workshop highlights include:

Delving into ADC bioconjugation: What is the chemistry behind building ADCs?
Assessing the pros and cons of different conjugation methods across sitespecific and click chemistries, including biorthogonal methods
Breaking down the foresight and innovation during discovery to maximise differentiated ADC performance in the clinic

Workshop F

Tailored to Preclinical & Translation Content

1:00 pm Optimising Preclinical Model Deployment & Strategy to Tackle ADC & Novel Conjugate Translational Mismatch

Harry Copping

PhD, GSK & University of Strathclyde

Rakesh Dixit

President & Chief Executive Officer, Bionavigen Oncology

Deryk Loo

Vice President, MacroGenics

Despite ADC’s raging success in oncology in the clinic, translational barriers still plague ADC development, with preclinical activity not matching early clinical safety and efficacy readouts and therapeutic index

As the field turns its attention to advance novel conjugate translation, join your peers to best leverage preclinical tools and understand rationale to effectively characterise safety and efficacy to minimise the ADC translational mismatch

Workshop highlights include:

Gleaning insights from PDX models alongside emerging capabilities and challenges from in vitro and organoid models
Understanding translational considerations for novel conjugates including bispecific ADCs and combination therapies
Delving into in vitro pharmacology studies with high content imaging to better understand ADC trafficking, favourable design characteristics and considerations for nonspecific uptake

Workshop G

Tailored to Clinical Lessons Content

1:00 pm Navigating Clinical Utility Index Approaches & Clinical Pharmacology Strategy to Optimise ADC Dose Selection

Venkatesh Pilla Reddy

Senior Director, Global PKPD & Pharmacometrics, Eli Lilly & Co.

Eunice Yuen

Director, PK/PD & Pharmacometrics, Eli Lilly & Co.

Daniel Bending

Postdoctoral Researcher, Eli Lilly & Co.

Navigating dose escalation and selection is a crucial stage in early development to set up ADC performance for success under Project Optimus guidelines

Don’t miss this Eli Lilly-led workshop to delve into all things ADC clinical pharmacology across quantitative systems pharmacology and clinical utility index approaches to optimise your ADC dose selection

Workshop highlights include:

Utilising quantitative systems pharmacology to investigate ADC preclinical PK/PD characterisation
Leveraging clinical utility index approach to assess the benefit-risk profiles of ADCs
Understanding ADC-specific clinical pharmacology considerations and assessing lessons learnt from ADC dose capping

Workshop H

Tailored to Manufacturing & Supply Chain Content

1:00 pm Delving Into Strategy & Stakeholder Management to Optimise ADC Outsourcing & Supply Chain

Herbert Ogutu

Senior Manager, Contract Development & Manufacturing, Amgen

Sonia Appel

Founder, Alismere

Daniel Higazi

Vice President, Biologics Pharmaceutical Development, CMC, Ipsen Pharma

Identifying, selecting and maintaining strong relationships with external manufacturing partners is vital to navigate the complex global ADC supply chain, often with multiple CMO partners whilst under accelerated ADC development timelines

Join this strategy-led workshop to navigate selection criteria and best practices to ensure beneficial relationships with outsourcing partners and de-risk your ADC manufacturing and supply

Workshop highlights include:

Discussing opportunities to establish and maintain effective collaboration between sponsor companies and CMOs
Breaking down criteria considerations to assess and prioritise manufacturing partner selection
Assessing challenges in ADC drug-linker manufacturing and supply to understand key risk factors and deploy best strategies for mitigation management

4:00 pm End of Post Conference Workshop Day

Post-Conference Workshop Day

Explore the Agenda

8:00 am Check In, Morning Coffee & Light Refreshments

Workshop A

9:00 am Examining The Need for Novel ADC Payload Mechanisms: What Progress Has Been Made & What is Yet to be Demonstrated?

Workshop B

9:00 am Using Computational Approaches for Early-Stage Design & Late-Stage ADC Development

Workshop C

9:00 am Connecting ADC Design to Performance: How is Each Component Contributing to ADC Clinical Safety & Efficacy?

Workshop D

9:00 am Understanding Process Control & Scale-Up to Develop Robust Processes for Complex Conjugates Across Development Stages

12:00 pm Lunch & Networking

Workshop E

1:00 pm Deep Diving into ADC Chemistry Conjugation to Understand the Fundamentals Behind Next-Generation ADC Properties & Design

Workshop F

1:00 pm Optimising Preclinical Model Deployment & Strategy to Tackle ADC & Novel Conjugate Translational Mismatch

Workshop G

1:00 pm Navigating Clinical Utility Index Approaches & Clinical Pharmacology Strategy to Optimise ADC Dose Selection

Workshop H

1:00 pm Delving Into Strategy & Stakeholder Management to Optimise ADC Outsourcing & Supply Chain

4:00 pm End of Post Conference Workshop Day

Venue

Map

Contact

Join Our Team

About Us

Explore Our Products

Stay Connected

Search

Organised By